NEW YORK (GenomeWeb News) – Genetic Technologies announced today it received a further ex parte re-examination certificate from the US Patent and Trademark Office for certain claims related to the company's non-coding DNA patent.

The Australian firm said that the certificate follows the third request for ex parte re-examination by Duluth, Ga.-based Merial of claims 1-15, 17, 18, 26-29, and 32 of US Patent No. 5,612,179. In the certificate, the USPTO confirms the patentability of all the claims, and no amendments were made to the '179 patent, GTG said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.